<DOC>
	<DOCNO>NCT01987297</DOCNO>
	<brief_summary>In prospective randomize study patient newly diagnose acute promyelocytic leukemia , patient randomize two group receive retinoic acid arsenic trioxide base treatment versus retinoic acid chemotherapy base regimen .</brief_summary>
	<brief_title>Combined Retinoic Acid , Arsenic Trioxide Chemo Newly-diagnosed APL</brief_title>
	<detailed_description>In prospective randomize study patient newly diagnose acute promyelocytic leukemia . For induction , patient randomize two group receive treatment compose retinoic acid combine arsenic trioxide versus retinoic acid combine chemotherapy . For consolidation , experimental group recieved 2 cycle ATRA+arsenic control group recieved two cycle ATRA+idarubicin daunorubicin . After consolidation , patient achieve molecular remission recieved 5 cycle maintenance treatment ATRA arsenic . In case intermediate high-risk disease , cytarabine add consolidation .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>newlydiagnosed patient acute promyelocytic leukemia via cytogenetics molecular assay Age : 1865 Hepatic/renal function : Bil≤35μmol/L，AST/ALT le 2Xnormal range , Cr 150μmol/L Normal cardial function Informed consent Relapsed patient Known history arsenic allergy QT interval &gt; 450ms Other malignanct disease Pregnant patient Patients mental illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>arsenic</keyword>
	<keyword>acute promyelocytic leukemia</keyword>
	<keyword>outcome</keyword>
</DOC>